Aktienanalyse zu Cellebrite DI Ltd (CLBT)CLBTCellebrite DI Ltd

Cellebrite DI Ltd is an Israel-based company engaged primarily in the software sector. The Company is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Company provides solutions for the public and private sectors, enabling organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. The Company's platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. The Company aims to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. It operates in the Technology sector.

Cellebrite DI Ltd is currently not a strong buy due to its recent performance and outlook. The stock is priced at $11.26, with a significant year-to-date decline of 36.88%. The forward P/E ratio is 35.71, indicating that the stock may be overvalued compared to its earnings potential. Additionally, the company recently lowered its 2026 revenue guidance to between $555 million and $561 million, below analyst expectations, which raises concerns about future growth.